Wilson Sonsini Goodrich & Rosati advised Iambic Therapeutics on the transaction. Iambic Therapeutics (Iambic), a clinical-stage biotechnology company, announced the closing of an oversubscribed $50 million...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented Halia Therapeutics in the transaction. Halia Therapeutics announced it raised $30 million in Series C financing round led by Todd Pedersen, with continued...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented Edgewise Therapeutics on the transaction, and Cooley represented the underwriters. Edgewise Therapeutics, Inc. (“Edgewise”) (NASDAQ: EWTX) announced the pricing of an underwritten...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Iambic on the transaction. Iambic Therapeutics announced the closing of an oversubscribed $100 million Series B financing. The round was co-led by...
You must be a Standard 1 Year member to access this content.
